• U Budde and R Schneppenheim.
• Prof. Dr. Ulrich Budde, MEDILYS Laborgesellschaft mbH, c/o ASKLEPIOS Klinik Altona, Zentrales Labor, Paul-Ehrlich-Straße 1, 22763 Hamburg, Germany, Tel. +49/(040)/18 18 81-59 75 Fax -49 48, E-mail: u.budde@asklepios.com, www.medilys.de.
• Hamostaseologie. 2014 Jan 1; 34 (3): 215-25.

AbstractThe function of von Willebrand factor (VWF), a huge multimeric protein and a key factor in platelet dependent primary haemostasis, is regulated by its specific protease ADAMTS13. The ADAMTS13 dependent degradation of VWF to its proteolytic fragments can be visualized as a characteristic so-called triplet structure of individual VWF oligomers by multimer analysis. Lack of VWF high molecular weight multimers (VWF-HMWM) or their pathologically enhanced degradation underlies a particular type of von Willebrand disease, VWD type 2A with a significant bleeding tendency, and may also be observed in acquired von Willebrand syndrome due to cardiovascular disease. In these conditions multimer analysis is an obligatory and powerful tool for diagnosis of VWD. The opposite condition, the persistence of ultralarge VWF (UL-VWF) multimers may cause the microangiopathic life-threatening disorder thrombotic thrombocytopenic purpura (TTP). During the course of active TTP, UL-VWF is consumed in the hyaline thrombi formed in the microvasculature which will ultimately result in the loss of UL-VWF and VWF-HMWM. Therefore, VWF multimer analysis is not a valid tool to diagnose TTP in the active phase of disease but may be helpful for the diagnosis of TTP patients in remission.

25 keywords...

hide…